BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 21598360)

  • 1. A pharmacogenetic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease.
    Wu X; Katz E; Della Valle MC; Mascioli K; Flanagan JJ; Castelli JP; Schiffmann R; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
    Hum Mutat; 2011 Aug; 32(8):965-77. PubMed ID: 21598360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.
    Benjamin ER; Flanagan JJ; Schilling A; Chang HH; Agarwal L; Katz E; Wu X; Pine C; Wustman B; Desnick RJ; Lockhart DJ; Valenzano KJ
    J Inherit Metab Dis; 2009 Jun; 32(3):424-40. PubMed ID: 19387866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.
    Benjamin ER; Della Valle MC; Wu X; Katz E; Pruthi F; Bond S; Bronfin B; Williams H; Yu J; Bichet DG; Germain DP; Giugliani R; Hughes D; Schiffmann R; Wilcox WR; Desnick RJ; Kirk J; Barth J; Barlow C; Valenzano KJ; Castelli J; Lockhart DJ
    Genet Med; 2017 Apr; 19(4):430-438. PubMed ID: 27657681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice.
    Benjamin ER; Khanna R; Schilling A; Flanagan JJ; Pellegrino LJ; Brignol N; Lun Y; Guillen D; Ranes BE; Frascella M; Soska R; Feng J; Dungan L; Young B; Lockhart DJ; Valenzano KJ
    Mol Ther; 2012 Apr; 20(4):717-26. PubMed ID: 22215019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.
    Oommen S; Zhou Y; Meiyappan M; Gurevich A; Qiu Y
    Mol Genet Metab; 2019 May; 127(1):74-85. PubMed ID: 31036492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.
    Besada P; Gallardo-Gómez M; Pérez-Márquez T; Patiño-Álvarez L; Pantano S; Silva-López C; Terán C; Arévalo-Gómez A; Ruz-Zafra A; Fernández-Martín J; Ortolano S
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.
    Ishii S; Chang HH; Kawasaki K; Yasuda K; Wu HL; Garman SC; Fan JQ
    Biochem J; 2007 Sep; 406(2):285-95. PubMed ID: 17555407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.
    Siekierska A; De Baets G; Reumers J; Gallardo R; Rudyak S; Broersen K; Couceiro J; Van Durme J; Schymkowitz J; Rousseau F
    J Biol Chem; 2012 Aug; 287(34):28386-97. PubMed ID: 22773828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
    Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
    PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.
    Giugliani R; Waldek S; Germain DP; Nicholls K; Bichet DG; Simosky JK; Bragat AC; Castelli JP; Benjamin ER; Boudes PF
    Mol Genet Metab; 2013 May; 109(1):86-92. PubMed ID: 23474038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat.
    Braunstein H; Papazian M; Maor G; Lukas J; Rolfs A; Horowitz M
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort.
    Nowak A; Huynh-Do U; Krayenbuehl PA; Beuschlein F; Schiffmann R; Barbey F
    J Inherit Metab Dis; 2020 Mar; 43(2):326-333. PubMed ID: 31449323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease.
    Lukas J; Cimmaruta C; Liguori L; Pantoom S; Iwanov K; Petters J; Hund C; Bunschkowski M; Hermann A; Cubellis MV; Rolfs A
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
    Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
    PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
    Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
    J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
    Germain DP; Hughes DA; Nicholls K; Bichet DG; Giugliani R; Wilcox WR; Feliciani C; Shankar SP; Ezgu F; Amartino H; Bratkovic D; Feldt-Rasmussen U; Nedd K; Sharaf El Din U; Lourenco CM; Banikazemi M; Charrow J; Dasouki M; Finegold D; Giraldo P; Goker-Alpan O; Longo N; Scott CR; Torra R; Tuffaha A; Jovanovic A; Waldek S; Packman S; Ludington E; Viereck C; Kirk J; Yu J; Benjamin ER; Johnson F; Lockhart DJ; Skuban N; Castelli J; Barth J; Barlow C; Schiffmann R
    N Engl J Med; 2016 Aug; 375(6):545-55. PubMed ID: 27509102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong increase of leukocyte apha-galactosidase A activity in two male patients with Fabry disease following oral chaperone therapy.
    Lamari F; Mauhin W; Koraichi F; Khrouf W; Bordet C; London J; Lidove O; Charron P
    Mol Genet Genomic Med; 2019 Sep; 7(9):e894. PubMed ID: 31393666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.
    Shin SH; Kluepfel-Stahl S; Cooney AM; Kaneski CR; Quirk JM; Schiffmann R; Brady RO; Murray GJ
    Pharmacogenet Genomics; 2008 Sep; 18(9):773-80. PubMed ID: 18698230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.
    Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Barisoni L; Jennette CJ; Bragat A; Castelli J; Sitaraman S; Lockhart DJ; Boudes PF
    Orphanet J Rare Dis; 2012 Nov; 7():91. PubMed ID: 23176611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.